BlackRock Amends Vanda Pharma Stake, Signals Portfolio Shift
Ticker: VNDA · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, portfolio-change
TL;DR
**BlackRock updated its Vanda Pharma holdings, watch for market reaction.**
AI Summary
BlackRock, Inc. filed an amended Schedule 13G/A on January 23, 2024, indicating a change in their ownership stake in Vanda Pharmaceuticals Inc. as of December 31, 2023. This filing, Amendment No. 5, updates their previous disclosures regarding their holdings of Vanda's Common Stock. This matters to investors because BlackRock is a major institutional investor, and changes in their position can signal their sentiment about the stock's future prospects, potentially influencing other investors.
Why It Matters
This filing shows BlackRock's updated ownership in Vanda Pharmaceuticals, which can influence market perception and potentially impact the stock price due to the size and influence of BlackRock.
Risk Assessment
Risk Level: low — This is a routine update from a large institutional investor and does not inherently signal high risk, though the underlying change in ownership could be interpreted differently.
Analyst Insight
An investor should review the full SC 13G/A filing to understand the specific changes in BlackRock's ownership percentage and share count, as this filing only indicates an amendment without providing the new figures in the provided text. This information could inform their own investment decisions regarding Vanda Pharmaceuticals Inc.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person filing the SC 13G/A
- Vanda Pharmaceuticals Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
- Amendment No: 5 (number) — the specific amendment number of the filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5)' sections.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as indicated under '(1)Names of reporting persons. BlackRock, Inc.'.
What is the subject company whose securities are being reported?
The subject company is Vanda Pharmaceuticals Inc., as stated under 'VANDA PHARMACEUTICALS INC (Name of Issuer)'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of Vanda Pharmaceuticals Inc. is 921659108, as listed under 'CUSIP No. 921659108'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Vanda Pharmaceuticals Inc. (VNDA).